Corvus Pharmaceuticals Inc. (CRVS) Soars 5.17%

Corvus Pharmaceuticals Inc. (CRVS) Soars 5.17%

Corvus Pharmaceuticals Inc. (CRVS) had a good day on the market for Friday October 11 as shares jumped 5.17% to close at $3.05. About 78,456 shares traded hands on 709 trades for the day, compared with an average daily volume of n/a shares out of a total float of 29.39 million. After opening the trading day at $2.92, shares of Corvus Pharmaceuticals Inc. stayed within a range of $3.19 to $2.81.

With today’s gains, Corvus Pharmaceuticals Inc. now has a market cap of $89.64 million. Shares of Corvus Pharmaceuticals Inc. have been trading within a range of $9.07 and $2.53 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing small molecule and antibody agents that target the immune system to treat patients with cancer.

Corvus Pharmaceuticals Inc. is based out of Burlingame, CA and has some 49 employees. Its CEO is Richard A. Miller.

Corvus Pharmaceuticals Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!